Last quarter (Q3 2023), Sonnet BioTherapeutics Holdings's total revenue was $36.85K, a decrease of -40.63% from the same quarter last year. In Q3, Sonnet BioTherapeutics Holdings's net income was $-3.95M. See Sonnet BioTherapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	$ 173.30K	$ 349.94K	$ 483.63K	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 110.55K	$ 349.94K	-	-	-
Operating Expense	$ 41.02K	$ -30.02M	$ 25.57M	$ 17.41M	$ 4.71M
Operating Income	$ -11.17M	$ -29.67M	$ -25.09M	$ -17.41M	$ -4.71M
Net Non Operating Interest Income Expense	-	-	$ 15.00	$ 20.68K	$ -162.87K
Other Income Expense	$ -131.67K	$ -300.00K	$ 103.46K	$ -6.87M	-
Pretax Income	$ -11.19M	$ -29.72M	$ -24.98M	$ -24.27M	$ -4.87M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -11.19M	$ -29.72M	$ -24.98M	$ -65.60M	$ -4.87M
Basic EPS	$ -2.93	$ -6.84	$ -14.28	$ -6.96	$ -23.66
Diluted EPS	$ -2.13	-	$ -14.28	$ -6.96	$ -23.66
Basic Average Shares	$ 57.26M	$ 4.35M	$ 1.75M	$ 9.42M	$ 205.70K
Diluted Average Shares	$ 51.43M	-	$ 1.75M	$ 9.42M	$ 205.70K
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 41.02K	$ -30.02M	$ 25.57M	$ 17.41M	$ 4.71M
Net Income From Continuing And Discontinued Operation	$ -22.59M	$ -29.72M	$ -24.98M	$ -24.27M	$ -4.87M
Normalized Income	$ -10.49M	-	$ -24.96M	$ -17.39M	$ -4.87M
Interest Expense	-	-	-	-	-
EBIT	$ -11.13M	$ -29.72M	$ -25.09M	$ -17.41M	$ -4.71M
EBITDA	$ -11.06M	$ -29.63M	$ -24.99M	$ -17.35M	$ -4.71M

Currency in USD

Sonnet BioTherapeutics Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing